Neuropatie polekowe

• Authors: Banach Marta , Juranek Judyta , Antczak Jakub
• Languages of publication: PL

Keywords

PL

neurotoksyczność; statyny polekowe neuropatie; amiodaron; talidomid; bortezomib

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2015
• Issue: 4
• Pages: 284-288

Contributors

author

Banach Marta

author

Juranek Judyta

author

Antczak Jakub

References

• Seretny M, Currie GL, Sena ES, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy:a systematic review and meta-analysis. Pain 2014; 155(12): 2461–2470.
• Tisdale JE, Miller DA. Drug-induced diseases: prevention, detection, and management. Bethesda: ASHP; 2010.
• Bainbridge JL. Experimental and clinical neurotoxicology. Am J Pharm Educ 2000; 64: 335.
• Russell JW, Gill JS, Sorenson EJ, et al. Suramin-induced neuropathy in an animal model. J Neurol Sci 2001; 192(1–2): 71–80.
• Hoke A, Ray M. Rodent models of chemotherapy-induced peripheral neuropathy. ILAR J 2014; 54(3): 273–281.
• Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009; 9(1): 69–75.
• Camdessanche JP, Jousserand G, Ferraud K, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain 2009; 132(Pt 7): 1723–1733.
• Ta LE, Espeset L, Podratz J, et al. Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum- DNA binding. Neurotoxicology 2006; 27(6): 992–1002.
• Preston DC, Shapiro BE. Electromyography and neuromuscular disorders: clinical-electrophysiologic correlations (expert consult-online). Elsevier Health Sciences; 2012.
• Cata JP, Weng HR, Lee BN, et al. Clinical and experimental findings in humans and animals with chemotherapy-induced peripheral neuropathy. Minerva Anestesiol 2006; 72(3): 151–169.
• Kimura J. Electrodiagnosis in diseases of nerve and muscle: principles and practice. Oxford: Oxford University Press; 2013.
• Weiss LD, Weiss JM, Silver JK. Easy EMG: a guide to performing nerve conduction studies and electromyography. Elsevier Health Sciences; 2015.
• Auer J, Berent R, Eber B. Amiodarone in the prevention and treatment of arrhythmia. Curr Opin Investig Drugs 2002; 3(7):1037–1044.
• Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66(7): 865–869.
• Fraser AG, McQueen IN, Watt AH, et al. Peripheral neuropathy during longterm high-dose amiodarone therapy.J Neurol Neurosurg Psychiatry 1985; 48(6): 576–578.
• Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998; 18(6 Pt 2): 138S–145S.
• Palakurthy PR, Iyer V, Meckler RJ. Unusual neurotoxicity associated with amiodarone therapy. Arch Intern Med 1987; 147(5):881–884.
• Ricaurte B, Guirguis A, Taylor HC, et al. Simvastatin-amiodarone interaction resulting in rhabdomyolysis, azotemia, and possible hepatotoxicity. Ann Pharmacother 2006; 40(4): 753–757.
• Roten L, Schoenenberger RA, Krahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004; 38(6): 978–981.
• Saliba WR, Elias M. Myopathy from the combination of simvastatin and amiodarone. Eur J Intern Med 2006; 17(2): 148.
• Raeder EA, Podrid PJ, Lown B. Side effects and complications of amiodarone therapy. Am Heart J 1985; 109(5 Pt 1): 975–983.
• Morady F, Sauve MJ, Malone P, et al. Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation. Am J Cardiol 1983; 52(8): 975–979.
• Kashyap AS, Anand KP, Kashyap S. Severe ataxia caused by amiodarone. Am J Cardiol 2006; 97(10): 1550–1551.
• Phan T, McLeod JG, Pollard JD, et al. Peripheral neuropathy associated with simvastatin. J Neurol Neurosurg Psychiatry 1995;58(5): 625–628.
• Charness ME, Morady F, Scheinman MM. Frequent neurologic toxicity associated with amiodarone therapy. Neurology 1984;34(5): 669.
• . Meier C, Kauer B, Muller U, et al. Neuromyopathy during chronic amiodarone treatment. A case report. J Neurol 1979; 220(4):231–239.
• Lustman F, Monseu G. Letter: amiodarone and neurological side-effects. Lancet 1974; 1(7857): 568.
• Pellissier JF, Pouget J, Cros D, et al. Peripheral neuropathy induced by amiodarone chlorhydrate. A clinicopathological study.J Neurol Sci 1984; 63(2): 251–266.
• Jacobs JM, Costa-Juss F. The pathology of amiodarone neurotoxicity. Brain 1985; 108(Pt 3): 753–769.
• Lamon-Fava S. Statins and lipid metabolism: an update. Curr Opin Lipidol 2013; 24(3): 221–226
• Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochr Database Syst Rev 2013; 1: CD004816.
• Baker SK, Tarnopolsky MA. Statin-associated neuromyotoxicity. Drugs Today (Barc) 2005; 41(4): 267–293.
• Bays H. Statin safety: an overview and assessment of the data – 2005. Am J Cardiol 2006; 97(8A): 6C–26C.
• Gaist D, Jeppesen U, Andersen M, et al. Statins and risk of polyneuropathy A case-control study. Neurology 2002; 58(9):1333–1337.
• Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + antystatin. Am J Cardiol 2005; 95(1): 120–122.
• Cziraky MJ, Willey VJ, McKenney JM, et al. Risk of hospitalized rhabdomyolysis associated with lipid-lowering drugs in a real-world clinical setting. J Clin Lipidol 2013; 7(2): 102–108.
• Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study.Epidemiology 2001; 12(5): 565–569.
• Law M, Rudnicka AR. Statin safety: a systematic review. Am J Cardiol 2006; 97(8A): 52C–60C.
• Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives.Curr Cancer Drug Targets 2011; 11(3): 239–253.
• Cavaletti G, Jakubowiak AJ. Peripheral neuropathy during bortezomib treatment of multiple myeloma: a review of recent studies.Leuk Lymphoma 2010; 51(7): 1178–1187.
• Weimer LH, Sachdev N. Update on medication-induced peripheral neuropathy. Curr Neurol Neurosci Rep 2009; 9(1): 69–75.
• Zivkovic SA, Lacomis D, Lentzsch S. Paraproteinemic neuropathy. Leuk Lymphoma 2009; 50(9): 1422–1433.
• Argyriou AA, Iconomou G, Kalofonos HP. Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature. Blood 2008; 112(5): 1593–1599.
• Chaudhry V, Cornblath DR, Polydefkis M, et al. Characteristics of bortezomib- and thalidomide-induced peripheral neuropathy.J Peripher Nerv Syst 2008; 13(4): 275–282.
• Gupta S, Pagliuca A, Devereux S, et al. Life-threatening motor neurotoxicity in association with bortezomib. Haematologica 2006; 91(7): 1001.
• Richardson PG, Xie W, Mitsiades C, et al. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27(21):3518–3525.
• Richardson PG, Briemberg H, Jagannath S, et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24(19): 3113–3120.
• Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenström’s macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007; 25(12): 1570–1575.
• Umapathi T, Chaudhry V. Toxic neuropathy. Curr Opin Neurol 2005; 18(5): 574–580.
• Windebank AJ, Grisold W. Chemotherapy-induced neuropathy. J Peripher Nerv Syst 2008; 13(1): 27–46.
• Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000; 96(9): 2943–2950.
• Cavaletti G, Beronio A, Reni L, et al. Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study. Neurology 2004; 62(12): 2291–2293.
• Plasmati R, Pastorelli F, Cavo M, et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study.Neurology 2007; 69(6): 573–581.
• Laaksonen S, Remes K, Koskela K, et al. Thalidomide therapy and polyneuropathy in myeloma patients. Electromyogr Clin Neurophysiol 2005; 45(2): 75–86
• Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology 2003; 60(5): 877–878.
• Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 2006; 24(27): 4507–4514.
• Offidani M, Corvatta L, Marconi M, et al. Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy. Eur J Haematol 2004; 72(6): 403–409.
• Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term (> 1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol 2005; 74(3): 212–216.
• Hess C, Hunziker T, Küpfer A, et al. Thalidomide-induced peripheral neuropathy. J Neurol 1986; 233(2): 83–89.
• Moore CD. Management of chemotherapy-induced peripheral neuropathy. US Pharm 2015; 40(1): HS5–HS10.
• Cavaletti G, Frigeni B, Lanzani F, et al. Chemotherapy-induced peripheral neurotoxicity assessment: a critical revision of the currently available tools. Eur J Cancer 2010; 46(3): 479–494.
• Tariman JD, Love G, McCullagh E, et al. Peripheral neuropathy associated with novel therapies in patients with multiple myeloma:consensus statement of the IMF Nurse Leadership Board. Clin J Oncol Nurs 2008; 12(3 Suppl): 29.
• Bilińska M, Usnarska-Zubkiewicz L, Pokryszko-Dragan A. Bortezomib-induced painful neuropathy in patients with multiple myeloma. Contemp Oncol (Pozn) 2013; 17(5): 421–426.
• Bilińska M, Usnarska-Zubkiewicz L, Szymczyk M, et al. Thalidomide-induced sensory neuropaty in patients with multiple myeloma. Pol Merk Lek 2011; 31(182): 86–91..